Kiora Pharmaceuticals INC

Kiora Pharmaceuticals has entered into an exclusive license agreement with Chong Kun Dang Pharmaceutical Corporation (CKD) for the development and commercialization of KIO-301 in South Korea.

Kiora Pharmaceuticals announced its second quarter 2026 financial results, highlighting progress in its Phase 2 trials for KIO-301 and KIO-104, and an extended operational runway into late 2028.

Kiora Pharmaceuticals announced preclinical data demonstrating that its ion channel modulator, KIO-300, significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy model.

Kiora Pharmaceuticals announced first quarter 2026 financial results and provided updates on its clinical pipeline, highlighting active enrollment in Phase 2 studies and a strengthened balance sheet.

Kiora Pharmaceuticals has closed a private placement financing for $5 million in upfront gross proceeds with up to $19 million in potential future warrant exercises.

Kiora Pharmaceuticals announced the departure of its Chief Development Officer, Eric J. Daniels, M.D., MBA, effective April 17, 2026, to pursue other opportunities.

Kiora Pharmaceuticals, Inc. (KPRX) filed its Form 10-Q for the quarter ended June 30, 2026, detailing progress in its clinical-stage retinal disease programs, strategic collaborations, and financial position.

Kiora Pharmaceuticals reports a net loss of $2.42 million for Q1 2026, with cash reserves projected to fund operations into late 2028 following a recent financing.

Kiora Pharmaceuticals reports Q3 2025 results, highlighting progress in KIO-301 and KIO-104 clinical trials and extending its cash runway into late 2027.

Kiora Pharmaceuticals reported a net loss for Q2 2025, contrasting with prior year's income, while advancing its KIO-301 and KIO-104 ophthalmic drug candidates into Phase 2 trials and securing a new option agreement.

Kiora Pharmaceuticals reports a net loss of $2.19 million for Q1 2025, compared to a net income of $13.45 million in Q1 2024, primarily due to the recognition of collaboration revenue in the prior year and increased R&D expenses.

Kiora Pharmaceuticals reported a net income of $7.8 million for the nine months ended September 30, 2024, driven by a $16 million upfront payment from a strategic collaboration.

Kiora Pharmaceuticals reported a net loss of $10.8 million for 2025, driven by increased R&D spending on its KIO-104 and KIO-301 programs and an impairment charge, despite securing key partnerships and maintaining liquidity into late 2027.

Kiora Pharmaceuticals announces its FY2024 results, marked by a strategic partnership with TOI for KIO-301 and progress in clinical trials for retinal diseases.

Kiora Pharmaceuticals' 2023 annual report details a year of strategic shifts, clinical trial advancements, and a significant partnership to propel its retinal disease therapies.

Kiora Pharmaceuticals CFO Melissa Tosca reported a transaction involving the sale of common stock.

Kiora Pharmaceuticals President and CEO Brian M. Strem reported a transaction involving the sale of 1,869 shares of common stock.

Director Carmine N. Stengone was granted 25,000 stock options under the company's 2024 Equity Incentive Plan.

Director Aron Shapiro was granted 25,000 stock options in Kiora Pharmaceuticals under the 2024 Equity Incentive Plan.

Kiora Pharmaceuticals Director Erin Parsons received 25,000 stock options with an exercise price of $2.63, vesting fully by June 10, 2027.

Director David Hollander received 25,000 stock options with an exercise price of $2.63 as part of the company's equity incentive plan.

Kiora Pharmaceuticals announces its 2026 Annual Meeting of Stockholders to be held on June 10, 2026, featuring proposals for director elections, executive compensation, and an equity plan amendment.

Kiora Pharmaceuticals will hold its 2025 Annual Meeting of Stockholders on June 4, 2025, to elect directors, approve executive compensation, and ratify the appointment of its accounting firm.

Kiora Pharmaceuticals is asking stockholders to vote on proposals including a reverse stock split, increasing authorized shares, approving a new equity incentive plan, and other corporate governance matters at its upcoming annual meeting.

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have filed a corrected Schedule 13G to accurately report their beneficial ownership of Kiora Pharmaceuticals, Inc. common stock.

Nantahala Capital Management, LLC and its principals have reported a 9.99% beneficial ownership stake in Kiora Pharmaceuticals, Inc. as of March 31, 2026.

Alyeska Investment Group, L.P. has filed a Schedule 13G reporting beneficial ownership of 9.99% of Kiora Pharmaceuticals, Inc. common stock through warrant holdings.

Nantahala Capital Partners Limited Partnership has filed an amendment reporting beneficial ownership of 3.388% of Kiora Pharmaceuticals, Inc. common stock.

Rosalind Advisors and affiliated entities report a 9.9% potential beneficial ownership in Kiora Pharmaceuticals Inc. through warrants, subject to a blocker provision.

AIGH Capital Management and Orin Hirschman disclose a 4.9% beneficial ownership stake in Kiora Pharmaceuticals, Inc. as of December 31, 2025.